Switch theme
Sign up to access all valuation multiples
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.
1987
44
LTM Revenue $3.6M
LTM EBITDA -$37.2M
$165M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Immutep has a last 12-month revenue (LTM) of $3.6M and a last 12-month EBITDA of -$37.2M.
In the most recent fiscal year, Immutep achieved revenue of n/a and an EBITDA of -$27.4M.
Immutep expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Immutep valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $3.6M | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | $3.6M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$37.2M | XXX | -$27.4M | XXX | XXX | XXX |
| EBITDA Margin | -1025% | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$36.7M | XXX | -$29.9M | XXX | XXX | XXX |
| EBIT Margin | -1011% | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$34.8M | XXX | -$27.4M | XXX | XXX | XXX |
| Net Margin | -959% | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Immutep's stock price is AUD 0 (or $0).
Immutep has current market cap of AUD 415M (or $266M), and EV of AUD 257M (or $165M).
See Immutep trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $165M | $266M | XXX | XXX | XXX | XXX | $-0.02 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Immutep has market cap of $266M and EV of $165M.
Immutep's trades at n/a EV/Revenue multiple, and -5.1x EV/EBITDA.
Equity research analysts estimate Immutep's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Immutep has a P/E ratio of -7.7x.
See valuation multiples for Immutep and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $266M | XXX | $266M | XXX | XXX | XXX |
| EV (current) | $165M | XXX | $165M | XXX | XXX | XXX |
| EV/Revenue | 45.5x | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -4.4x | XXX | -5.1x | XXX | XXX | XXX |
| EV/EBIT | -4.5x | XXX | -4.9x | XXX | XXX | XXX |
| EV/Gross Profit | 45.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | -7.7x | XXX | -8.5x | XXX | XXX | XXX |
| EV/FCF | -4.8x | XXX | -5.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialImmutep's last 12 month revenue growth is -27%
Immutep's revenue per employee in the last FY averaged n/a, while opex per employee averaged $0.7M for the same period.
Immutep's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Immutep's rule of X is -1093% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Immutep and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -27% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -1025% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 17% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -1093% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.7M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Immutep acquired XXX companies to date.
Last acquisition by Immutep was XXXXXXXX, XXXXX XXXXX XXXXXX . Immutep acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Immutep founded? | Immutep was founded in 1987. |
| Where is Immutep headquartered? | Immutep is headquartered in Australia. |
| How many employees does Immutep have? | As of today, Immutep has 44 employees. |
| Who is the CEO of Immutep? | Immutep's CEO is Mr. Marc Voigt. |
| Is Immutep publicy listed? | Yes, Immutep is a public company listed on ASX. |
| What is the stock symbol of Immutep? | Immutep trades under IMM ticker. |
| When did Immutep go public? | Immutep went public in 1988. |
| Who are competitors of Immutep? | Similar companies to Immutep include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Immutep? | Immutep's current market cap is $266M |
| What is the current revenue of Immutep? | Immutep's last 12 months revenue is $3.6M. |
| What is the current revenue growth of Immutep? | Immutep revenue growth (NTM/LTM) is -27%. |
| What is the current EV/Revenue multiple of Immutep? | Current revenue multiple of Immutep is 45.5x. |
| Is Immutep profitable? | Yes, Immutep is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Immutep? | Immutep's last 12 months EBITDA is -$37.2M. |
| What is Immutep's EBITDA margin? | Immutep's last 12 months EBITDA margin is -1025%. |
| What is the current EV/EBITDA multiple of Immutep? | Current EBITDA multiple of Immutep is -4.4x. |
| What is the current FCF of Immutep? | Immutep's last 12 months FCF is -$34.2M. |
| What is Immutep's FCF margin? | Immutep's last 12 months FCF margin is -941%. |
| What is the current EV/FCF multiple of Immutep? | Current FCF multiple of Immutep is -4.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
